BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3878113)

  • 1. Deoxycoformycin in the treatment of leukemias and lymphomas.
    Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
    Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
    O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
    Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas.
    Spiers AS
    Ann N Y Acad Sci; 1985; 451():138-41. PubMed ID: 3878115
    [No Abstract]   [Full Text] [Related]  

  • 4. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 6. Deoxycoformycin in therapy of refractory lymphoid neoplasms.
    Ho AD; Thaler J; Kuse R; Willemze R; Mandelli F; Lauria F; Zittoun R; Stryckmans P
    Onkologie; 1988 Feb; 11(1):35-7. PubMed ID: 3283623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.
    Dearden CE; Matutes E; Hoffbrand AV; Ganeshaguru K; Brozovic M; Williams HJ; Traub N; Mills M; Linch DC; Catovsky D
    Br Med J (Clin Res Ed); 1987 Oct; 295(6603):873-5. PubMed ID: 2890401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
    Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
    Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
    Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
    J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.
    Daenen S; Rojer RA; Smit JW; Halie MR; Nieweg HO
    Br J Haematol; 1984 Dec; 58(4):723-7. PubMed ID: 6097297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
    Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
    Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
    Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell chronic lymphocytic leukaemia: anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2'-deoxycoformycin).
    Spiers AS; Davis MP; Levine M; Li CY; Mangan KF; Mazza JJ; Neu LT; O'Brien J; Rauch AE; Wiltsie JC
    Scand J Haematol; 1985 Jan; 34(1):57-67. PubMed ID: 2578689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.
    Grever MR; Bisaccia E; Scarborough DA; Metz EN; Neidhart JA
    Blood; 1983 Feb; 61(2):279-82. PubMed ID: 6600401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to deoxycoformycin in mature T cell malignancies.
    Ho AD; Stryckmans P; Zittoun R
    Br Med J (Clin Res Ed); 1987 Dec; 295(6611):1483-4. PubMed ID: 3500754
    [No Abstract]   [Full Text] [Related]  

  • 17. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
    Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.
    Spiers AS; Ruckdeschel JC; Horton J
    Scand J Haematol; 1984 Feb; 32(2):130-4. PubMed ID: 6608139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo effect of deoxycoformycin in human T cell leukemia.
    Yu AL; Kung FH; Bakay B; Nyhan WL
    Adv Exp Med Biol; 1979; 122B():373-9. PubMed ID: 397762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.